Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Xiao-Feng Powder (mXFP) is an investigational traditional Chinese medicine (TCM) herbal formulation developed by Professor Lin Zhixiu at the Chinese University of Hong Kong for the treatment of chronic urticaria. It is a refined version of the classic Xiao-Feng Powder (Wind-Dispersing Powder), a formula first documented in the 1617 TCM text *Orthodox Lineage of External Medicine* (Wai Ke Zheng Zong). The modification is tailored to enhance efficacy and safety for modern patients suffering from chronic spontaneous urticaria. In clinical trials, such as NCT04967092, mXFP is administered as oral granules in combination with second-generation antihistamines (e.g., bilastine) to evaluate its ability to reduce the Urticaria Activity Score (UAS7) and improve quality of life compared to antihistamine monotherapy. The formula traditionally acts by dispersing wind, clearing heat, and cooling the blood to address the underlying TCM diagnosis of 'Yin Zhen'.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Modified Xiao-Feng Powder.